TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8909433
Drug: L-threonine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine (4 g daily) with pyridoxal phosphate (160 mg daily)
Study: 8909433
Drug: BCAA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA and L-threonine
Study: 8909433
Drug: BCAA, L-threonine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA, L-threonine, and placebo
Study: 1474536
Drug: Nabumetone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1000 mg/day)
Study: 20456285
Drug: Multifaceted educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted educational intervention (1 day of didactic lectures, six 3-hour educational outreach visits, and an electronic reminder during drug prescribing)
Study: 7733042
Drug: Sugar fortified
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar fortified with 1 g FeNaEDTA and 15 mg retinol as retinyl palmitate/kg
Study: 2221586
Drug: Naloxone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.1 mg/kg)
Study: 30726693
Drug: Givosiran (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran (0.35 or 1.0 mg/kg) once-monthly injections in part B
Study: 30726693
Drug: Givosiran (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran (2.5 or 5.0 mg/kg) once-monthly injections in part C
Study: 30726693
Drug: Givosiran (0.035,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran (0.035, 0.10, 0.35, 1.0, or 2.5 mg/kg) single subcutaneous injection in part A
Study: 30726693
Drug: Givosiran (once-monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran (once-monthly or once-quarterly injections in part C)
Study: 26823793
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus cyclophosphamide (500 mg/m2 pemetrexed + 20 mg/kg cyclophosphamide)
Study: 26823793
Drug: Pemetrexed monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed monotherapy (500 mg/m2 pemetrexed)
Study: 25549103
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of propranolol HCl administered orally after memory reactivation phase.
Study: 22884505
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance dose)
Study: 22884505
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (fixed dose of 600 mg)
Study: 17623343
Drug: Treatment (T)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (T)
Study: 1336998
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose arginine-vasopressin (AVP)
Study: 1336998
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of arginine-vasopressin (AVP)
Study: 23599642
Drug: BB536-L (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB536-L (2.5 × 10¹⁰ cfu)
Study: 23599642
Drug: BB536-L and
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB536-L and BB536-H
Study: 19324253
Drug: Adjunctive cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive cilostazol (triple group; n = 30)
Study: 19324253
Drug: High maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance dose clopidogrel (high-MD group; n = 30)
Study: 19324253
Drug: Adjunctive cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive cilostazol (triple group)
Study: 19324253
Drug: High maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance dose clopidogrel (high-MD group)
Study: 16964595
Drug: HB‐AS04 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS04 vaccine (2 doses)
Study: 16964595
Drug: Licensed HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed HB vaccine (3 double doses)
Study: 16964595
Drug: HB‐AS04 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS04 vaccine (in subjects who did not undergo liver transplantation before booster)
Study: 16964595
Drug: Licensed HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed HB vaccine (in subjects who did not undergo liver transplantation before booster)
Study: 11794893
Drug: Short anticoagulant
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short anticoagulant course (3 months) for patients with temporary risk factors
Study: 11794893
Drug: Longer anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer anticoagulant course (6 months at least) for cases with permanent risk factors or idiopathic venous thromboembolism
Study: 11794893
Drug: 6-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week treatment for isolated calf vein thrombosis
Study: 11794893
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course of oral anticoagulant therapy
Study: 11794893
Drug: Low- or
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low- or fixed-dose oral anticoagulation
Study: 3060191
Drug: Nalbuphine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.15 mg kg‐1, intramuscular)
Study: 3060191
Drug: Haloperidol (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (oral, twice daily for 2 days)
Study: 31185775
Drug: Virtual kayak
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual kayak paddling (VKP) exercise for 60 min twice a week for 6 weeks
Study: 28237861
Drug: PF‐06291874 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06291874 15mg once daily for 28 days
Study: 28237861
Drug: PF‐06291874 35mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06291874 35mg once daily for 28 days
Study: 28237861
Drug: PF‐06291874 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06291874 75mg once daily for 28 days
Study: 28237861
Drug: PF‐06291874 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06291874 150mg once daily for 28 days
Study: 24022532
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral antibiotics (500 mg of kanamycin and 500 mg of metronidazole) plus intravenous antimicrobial prophylaxis
Study: 17468819
Drug: Intravenous antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antimicrobial prophylaxis alone
Study: 17067370
Drug: Motor imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor imagery training (daily mental rehearsal of movements with affected arm for 4 weeks)
Study: 9106560
Drug: Inhaled magnesium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled magnesium sulfate (4 mL; 286 mOsm)
Study: 20625021
Drug: Severely serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severely serum 25(OH)D deficient (levels <25 nmol/L)
Study: 20625021
Drug: Sufficient levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient levels of 25(OH)D (>/=75 nmol/L)
Study: 21197285
Drug: Preemptive lumiracoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive lumiracoxib 400 mg
Study: 21197285
Drug: Postoperative lumiracoxib
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative lumiracoxib 400 mg
Study: 16603063
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral prednisolone
Study: 14740601
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil (0.1 mg/kg)
Study: 11310385
Drug: Protein restricted
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein restricted diet (Group II, 25 patients, 0.6 g/kg/day, 50% high biological value)
Study: 9307742
Drug: Tiludronate 200
Normalized name: tiludronate 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiludronate 200 mg once daily
Study: 9307742
Drug: Tiludronate 400
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate 400 mg once daily
Study: 9307742
Drug: Tiludronate 600
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate 600 mg once daily
Study: 9307742
Drug: Tiludronate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiludronate (all doses)
Study: 29114972
Drug: ATRA and
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA and double induction intensified by high-dose cytosine arabinoside (HD ara‐C)
Study: 18677147
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine practices in menopausal management
Study: 15776267
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injections (Hylan G-F 20), 3 intra-articular injections at one-week intervals
Study: 17328957
Drug: Electro-convulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-convulsive therapy (ECT)
Study: 1955002
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) (250 micrograms.puff‐1), beginning with 1,000 micrograms daily
Study: 4084668
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of cibenzoline (8.00 am)
Study: 4084668
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of cibenzoline (10.00 pm)
Study: 30449071
Drug: Local treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment: surgery radiotherapy (55%)
Study: 30449071
Drug: Initial surgery
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial surgery without previous chemotherapy, with PORT
Study: 27050045
Drug: Yoga Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga Therapy (YT)
Study: 20600013
Drug: Peg‐IFNα‐2a 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFNα‐2a 180 μg every week
Study: 20600013
Drug: albIFN 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: albIFN 900 μg every 2 weeks
Study: 20600013
Drug: albIFN 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: albIFN 1200 μg every 2 weeks
Study: 18198165
Drug: Comprehensive Motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Motion Apparatus (CMA) treatment, thrice-weekly 30-min treatments for 12 weeks
Study: 16429317
Drug: pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (45 mg/day)
Study: 16429317
Drug: glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide (5 mg/day)
Study: 14738027
Drug: CA-125 level
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA-125 level > or = 43.1 U/mL in women with symptoms of imminent abortion
Study: 14738027
Drug: CA-125 level
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA-125 level threshold of 66.5 U/mL for patients with bleeding of > or = 3 days
Study: 10941601
Drug: Achillea drops
Normalized name: Achillea millefolium oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea drops (hydroalcoholic extract), 15-20 drops twice daily for more than 6 months
Study: 7767151
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg by mouth daily)
Study: 1588260
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg orally daily)
Study: 3709630
Drug: Carbamazepine (CBZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (CBZ), 10 mg kg‐1
Study: 25093998
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg twice daily) and Simvastatin (40 mg twice daily)
Study: 25093998
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg twice daily), Simvastatin (40 mg twice daily), and NaRLA (600 mg three times daily)
Study: 16179660
Drug: Testosterone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (0.5 mg sublingually)
Study: 10759624
Drug: nabumetone (1500-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabumetone (1500-2000 mg/day)
Study: 10759624
Drug: diclofenac SR
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac SR (100 mg/day)
Study: 10759624
Drug: piroxicam (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: piroxicam (20-30 mg/day)
Study: 28825422
Drug: MDMA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1 mg/kg) during encoding
Study: 28825422
Drug: MDMA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1 mg/kg) during retrieval
Study: 25394762
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg/kg) for 10 min preoperatively
Study: 22260216
Drug: Aprepitant 200
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 200 mg (p.o. given as a 2-hour pre-treatment)
Study: 22260216
Drug: Oxycodone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (20 and 40 mg/70 kg oral; 15 and 30 mg/70 kg intranasal)
Study: 18838046
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine (0.3 mg) with 10 mL of 0.75% ropivacaine
Study: 18838046
Drug: Systemic dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic dexmedetomidine (loading dose of 1 mug kg‐1 over 10 min followed by 0.4 mug kg‐1 h‐1)
Study: 18838046
Drug: Co-administered neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered neostigmine and dexmedetomidine
Study: 16809238
Drug: Telephone calls
Normalized name: Mosco Corn & Callus Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone calls promoting treatment adherence (initial call and biweekly calls)
Study: 24965167
Drug: Losartan (LS)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (LS) 50 mg
Study: 24965167
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Losartan (LS) 50 mg and Hydrochlorothiazide (HCTZ) 12.5 mg
Study: 22008090
Drug: With calcium
Normalized name: D3 with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: With calcium channel blocker (CCB) (n = 1807)
Study: 19506172
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex gum (4 mg, unflavored) for 4 weeks before and 8 weeks after the target quit date.
Study: 14709943
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at high doses
Study: 8956477
Drug: 280 mg
Normalized name: levodopa 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg GLY-GLN per kg body weight/day for 4 days
Study: 8956477
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg GLY-GLN per kg body weight/day for 4 days
Study: 8956477
Drug: 570 mg
Normalized name: peanut oil 570 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 570 mg GLY-GLN per kg body weight/day for 4 days
Study: 8956477
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition without GLY-GLN supplementation
Study: 1903813
Drug: Malathion lotion
Normalized name: Malathion Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malathion lotion
Study: 6998600
Drug: Proxicromil, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxicromil, administered orally before antigen challenge, dosage not specified, duration of action studied for at least 12 hours.
Study: 23179140
Drug: Single group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single group education session on APAP therapy
Study: 20443014
Drug: Angeliq (drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angeliq (drospirenone 2 mg and estradiol 1 mg)
Study: 14756978
Drug: Weekly meeting
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly meeting (WM) group
Study: 11716665
Drug: Physician recommendation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician recommendation of hormone replacement therapy (HRT)
Study: 9056061
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (80 g total dose, administered starting 4 h after sodium valproate)
Study: 8419816
Drug: Amoxicillin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (750 mg three times daily) plus Metronidazole (500 mg three times daily) for 12 days, along with Ranitidine (300 mg each night) for 6 or 10 weeks.
Study: 8419816
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 days, along with Ranitidine (300 mg each night) for 6 or 10 weeks.
Study: 31490311
Drug: 30% garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% garlic ointment
Study: 24824629
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg lithium carbonate
Study: 24824629
Drug: 1350 mg
Normalized name: HOMOSALATE 3060 mg in 45 mL / OCTOCRYLENE 4500 mg in 45 mL / OCTISALATE 2250 mg in 45 mL / AVOBENZONE 1350 mg in 45 mL TOPICAL CREAM [ZO Skin Health Daily Sheer Broad-Spectrum Sunscreen SPF 50 Water Resistant (40 Minutes)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1350 mg lithium carbonate
Study: 23121768
Drug: Heparin locks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin locks (thrice per week)
Study: 20130408
Drug: Crushed buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed buprenorphine tablets
Study: 20130408
Drug: Whole buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole buprenorphine tablets
Study: 20130408
Drug: Crushed placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed placebo tablets
Study: 20130408
Drug: Whole placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole placebo tablets
Study: 16114153
Drug: Oral 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 30% dextrose (2 ml)
Study: 16114153
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (2 ml)
Study: 10067266
Drug: SK-Plg (Streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK-Plg (Streptokinase + exogenous lys-plasminogen 7.5 mg)
Study: 7069582
Drug: Solution (1
Normalized name: Epidiolex 100mg/mL Solution (100mL Bottle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution (1 g of ascorbic acid)
Study: 7069582
Drug: Tablet (1
Normalized name: VOYDEYA Tablet (150mg Dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (1 g of ascorbic acid)
Study: 7069582
Drug: Timed-release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-release capsule (1 g of ascorbic acid)
Study: 7069582
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of ascorbic acid
Study: 28069563
Drug: Brief cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Study: 20646862
Drug: High-precision radiotherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-precision radiotherapy (three-dimensional conformal radiotherapy or intensity-modulated radiation therapy)
Study: 17520888
Drug: Emoxypine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxypine (150 mg every day for 14 days)
Study: 17520888
Drug: Mexidol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (300 mg a day for 14 days)
Study: 3370199
Drug: Gemeprost (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemeprost (1 mg vaginal pessary every 3 h for up to 5 pessaries)
Study: 3370199
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (150 mg per day for 4 days)
Study: 3370199
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (150 mg per day for 4 days) plus Gemeprost (1 mg on day 3)
Study: 30798472
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide 500 mg
Study: 30798472
Drug: Valproate sodium
Normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate sodium 400 mg
Study: 31102145
Drug: Adjuvant bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant bevacizumab with oxaliplatin-based chemotherapy
Study: 31102145
Drug: Standard oxaliplatin-based
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard oxaliplatin-based chemotherapy regimens
Study: 28916436
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (solifenacin 5mg and mirabegron 25mg, increased to 50mg at week 4)
Study: 26126306
Drug: Single-use negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-use negative pressure wound therapy (NPWT) system
Study: 21057704
Drug: MP-TF activity
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-TF activity before chemotherapy
Study: 21057704
Drug: MP-TF activity
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-TF activity after chemotherapy
Study: 17006119
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg intravenous lignocaine
Study: 31016855
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment